Exchange: NASDAQ·Updated 07:59 PM EST

TMDX News

News
all
press releases
Barrow Hanley Mewhinney & Strauss LLC Buys 837,530 Shares of TransMedics Group, Inc. $TMDX
Barrow Hanley Mewhinney & Strauss LLC acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 837,530 shares of the company's stock, valued at...
MarketBeat
Barrow Hanley Mewhinney & Strauss LLC Buys 837,530 Shares of TransMedics Group, Inc. $TMDX
Barrow Hanley Mewhinney & Strauss LLC acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 837,530 shares of the company's stock, valued at...
MarketBeat
More News
Stifel Nicolaus upped their price target on shares of TransMedics Group from $70.00 to $80.00 and gave the company a "hold" rating in a research report on Friday...
MarketBeat
TransMedics Group (NASDAQ:TMDX) Shares Cross Above 200 Day Moving Average - What's Next...
MarketBeat
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireNEW YORK, Nov. 12, 2026 Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or...
PR Newswire
When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?
Zacks
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
Zacks
When a stock breaks out above the 50-Day simple moving average, good things could be on the horizon. How should investors react?
Zacks
Gainers Obsidian Therapeutics (NASDAQ:OBX) stock increased by 27.7% to $12.26 during Friday's regular session. The company's market cap stands at $593.0 million. TransMedics Group (NASDAQ:TMDX) shares roseread more...
Benzinga
While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks
TransMedics (TMDX) delivered earnings and revenue surprises of +88.89% and +11.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.